Home>Drug Target Models>Immunotherapy Cells

Immunotherapy Cells

Immunotherapy mainly covers two disease fields: oncology and autoimmune disorders. Cancer immunotherapy activates the immune system to recognize and kill tumor cells through immune checkpoint blockade (PD-1/PD-L1), CAR-T cell therapy and immune pathway modulation. Autoimmune immunotherapy inhibits overactive immune responses by blocking inflammatory cytokines or immune cell functions to reduce self-tissue damage. To support immunotherapy drug R&D, ReqBio supplies a panel of cell screening models targeting IL12, 4-1BB, ERBB3, CD28, PD-1 and more.

Immunotherapy Cells

Case Study

CD3 agonist antibody dose response in CD3E KO NFAT-Luc Jurkat 2C24; parental NFAT-Luc Jurkat EC50 0.13 μg/ml, CD3E knockout abolishes luciferase RLU response

Figure 1. Dose response of CD3 Agonist Antibody in CD3E KO NFAT-Luc Jurkat (2C24)

CD3 agonist antibody triggers robust NFAT-Luc activation in parental Jurkat cells (EC50 = 0.13 μg/ml), while CD3E KO Jurkat cells show no reporter response, validating CD3E dependency of CD3 signaling.

Dose-response of CD38 & CD3E bispecific antibody AMG-424 in CD38 KO NFAT-Luc Jurkat (C8); co-culture with CD38+ Daudi cells yields EC50 = 27.1 ng/ml, control groups show EC50 >10000 ng/ml with minimal RLU signal

Figure 2. Dose Response of CD38&CD3E Bispecific Antibody in CD38 KO NFAT-Luc Jurkat(C8) with or without Daudi(CD38+)

Dose-response of CD38&CD3E bispecific antibody AMG-424 in CD38 KO NFAT-Luc Jurkat (C8); co-culture with CD38+ Daudi cells yields EC50 = 27.1 ng/ml, control groups show EC50 >10000 ng/ml with minimal RLU signal

Contact us

Name

Phone

Email*

Service & Products Interested*

Comments

submit
info@reqbio.com Email